Myo-inositol alters 13C-labeled fatty acid metabolism in human placental explants. Issue 1 (October 2019)

• Record Type: Journal Article
• Authors: Watkins, Oliver C; Islam, Mohammed Omedul; Selvam, Preben; Pillai, Reshma Appukuttan; Cazenave-Gassiot, Amaury; Bendt, Anne K; Karnani, Neerja; Godfrey, Keith M; Lewis, Rohan M; Wenk, Markus R; Chan, Shiao-Yng
• Is Part Of: Journal of endocrinology. Volume 243:Issue 1(2019)
• Page Start: 73
• Page End: 84
• Publication Date: 2019-10
• Subjects: placenta -- pregnancy -- fatty acids -- phospholipids -- metabolism; Endocrinology -- Periodicals; 616.4005
• DOI: 10.1530/JOE-19-0267
• Languages: English
• ISSNs: 0022-0795

Abstract

Abstract : We postulate that myo-inositol, a proposed intervention for gestational diabetes, affects transplacental lipid supply to the fetus. We investigated the effect of myo-inositol on fatty acid processing in human placental explants from uncomplicated pregnancies. Explants were incubated with 13 C-labeled palmitic acid, 13 C-oleic acid and 13 C-docosahexaenoic acid across a range of myo-inositol concentrations for 24 h and 48 h. The incorporation of labeled fatty acids into individual lipids was quantified by liquid chromatography mass spectrometry. At 24 h, myo-inositol increased the amount of 13 C-palmitic acid and 13 C-oleic-acid labeled lipids (median fold change relative to control = 1). Significant effects were seen with 30 µM myo-inositol (physiological) for 13 C-palmitic acid-lysophosphatidylcholines (1.26) and 13 C-palmitic acid-phosphatidylethanolamines (1.17). At 48 h, myo-inositol addition increased 13 C-oleic-acid-lipids but decreased 13 C-palmitic acid and 13 C-docosahexaenoic-acid lipids. Significant effects were seen with 30 µM myo-inositol for 13 C-oleic-acid-phosphatidylcholines (1.25), 13 C-oleic-acid-phosphatidylethanolamines (1.37) and 13 C-oleic-acid-triacylglycerols (1.32) and with 100 µM myo-inositol for 13 C-docosahexaenoic-acid-triacylglycerols (0.78). Lipids labeled with the same 13 C-fatty acid showed similar responses when tested at the same time point, suggesting myo-inositol alters upstream processes such as fatty acid uptake or activation. Myo-inositol supplementation may alter placental lipid physiology with unknown clinical consequences.